The Company expects to report preliminary results in mid-2025 from 12-month evaluable patients in the ongoing Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback